- Joined
- Aug 7, 2004
- Messages
- 170
- Reaction score
- 0
Last edited:
Haldol is available and is much safer in all respects, especially given IV, other than EPS risk of course.
For some reason EPS are allegedly not an issue with IV haldol...I've even heard practically non-existent (but I cannot substantiate this).
http://www.ncbi.nlm.nih.gov/pubmed/3597329
Still would worry about QT prolongation with IV haldol.
Really simple explanation with haldol being related to toursaddes and qtc-its because haldol has been used 1000 times more often and longer than anything else in hospital psychiatry hence most cases of toursades are from haldol but only because of the pure number of uses and not the relative risk being any higher than anything else.
WS, this is speculative.
Well of course it is interpreting the available data and making an opinion. But it is a completely reasonable opinion and widely accepted. There are objective data on exact qt prolongation of each antipsychotic. Haldol happens to be right in the middle of the bunch so this would not explain any icreased incidence with haldol. There are the most reported TDP cases from haldol use in the literature (objectively a search will reveal this-not my opinion) and objectively haldol has been used more times over the years than any other. Also objectively no other neuroleptic is used IV in the US anyway for delirium so this is not an opinion.
Of course something that is used much more frequently and used IV which is known to increase effective dose will increase risk of TDP. Nothing is special about IV but the problem it is not dosed correctly for IV, therefore people end up getting much higher relative doses since they often give the same "oral" doses only into the IV. That last part is my speculation. The rest is from pure data
Haldol is not "middle of the pack" for risk of QTc prolongation. It has among (if not the absolute) lowest per-dose-equivalent risk of prolonging the QTc of the neuroleptics.
here you are again spewing off incorrect data it is right smack about average for the antipsychotics.
For those who are running the old version of Vbulletin and can't actually see what is going on, Wallstreet is dangling awkwardly off the ropes and Doc Sampson has just given his hotel room number to the ring girl and told her to bring her sister.
QTc prolongation isn't what worries me. I really haven't seen too many problems with geodon. Its that rate of torsades. I don't think IV haldol is lowest in that category. Of course, we don't have a lot of comparison as I don't see a lot of other antipsychotics being given intravenously so its kind of a moot point...unless IV zyprexa is a safer (and available) option.
Also, doesn't zyprexa increase proinsulin c peptide and doesn't that protect against torsades? Not sure if that is correct.
So here is where WS might actually have a point. How do we estimate rate of TDP? The denominator for delirious patients receiving IV Haldol worldwide is massively larger than for any other neuroleptic, so just citing the number of reports of TDP with Haldol vs. anything else is inconclusive.
Beyond that - Haldol is a better choice for delirium than any atypical since the goal of treating delirium is to block dopamine and optimize acetylcholine. The anticholinergic load of the atypicals (in comparison to Haldol) makes them a poorer choice. Moreover, the sigma-1 antagonism of Haldol (that none of the atypicals have) have been shown to preserve neuronal stability and prevent cell death in states of oxidative stress (in animal models at least), which may well be the mechanism for the advantages of IV Haldol in delirium beyond 10 mg (which would block 99% of the D2 receptors).
WS - I'd be happy to give you the ref for that if you'd like once I get done with the ring girl and her sister.